Skip to main content
. 2021 Apr 29;22(9):4701. doi: 10.3390/ijms22094701

Figure 4.

Figure 4

TGFβ2 suppresses PGC-1α and ZLN005, the selective small molecular activator of PGC-1α, blocks TGFβ2-induced EMT. (A) Representative phase-contrast microscopy and immunofluorescence for vimentin (green) with DAPI at 72 h with or without TGFβ2 and/or ZLN005 (n = 3, scale bar is 50 μm) and (B) quantification of mean fluorescence intensity. Quantification of (C) PGC-1α and mesenchymal genes (D) α-SMA, (E) Snai1, (F) CTGF and (G) COL1A1 by qPCR at 24 h with or without TGFβ2 and/or ZLN005 treatment (n = 6). (H) Representative phase-contrast microscopy images for the scratch wound migration assay at 48 h with or without TGFβ2 and/or ZLN005 (n = 6, scale bar is 100 μm) and (I) quantification of percentage wound closure (n = 6). Significance was determined by one-way ANOVA with Tukey’s or Dunnet’s T3 post-hoc analysis. Error bars are means ± SEM. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns, not significant.